The bispectral index reads higher on remimazolam at the same depth

Design

randomised, double-blind, two-period crossover trial; confirmatory outcome prespecified

Population

16 healthy volunteers, American Society of Anesthesiologists physical status I

Primary outcome

mean bispectral index at deep sedation (clinical scale score of 1)

Effect

57.6 (SD 7.5) remimazolam vs 46.5 (SD 7.9) propofol; adjusted difference 11.1 units (95% CI 7.3-14.8)

The bispectral index was derived largely from propofol data, and whether its numbers mean the same thing under a benzodiazepine has not been settled. Sixteen healthy volunteers received remimazolam and propofol in random order at least a week apart, double-blind, each titrated to moderate and then deep sedation defined clinically by the Modified Observer's Assessment of Alertness and Sedation scale.

At deep sedation — the confirmatory outcome — mean index was 57.6 (SD 7.5) on remimazolam and 46.5 (SD 7.9) on propofol, an adjusted difference of 11.1 units (95% CI 7.3-14.8). The offset appeared at moderate sedation and at loss of the eyelash reflex as well. Emergence time did not differ between agents. In exploratory analysis, processing speed and executive function had recovered further at 30 minutes after remimazolam, with verbal memory no different and all domains converged by two hours.

The safety implication runs one way. A clinician titrating remimazolam to a propofol-derived index target — driving the number down to 40 to 60 — would be delivering deeper sedation than the number suggests, not lighter. The direction of error here is towards excess drug rather than towards awareness, which is the more reassuring of the two, but it is still a mismatch between what the monitor says and what the patient is.

Sixteen volunteers of physical status I is a mechanistic study, not a clinical population, and the authors say plainly that whether this warrants agent-specific reference values needs validating in patients. Until it is, the practical rule is to titrate remimazolam to clinical endpoints and treat the index as a trend rather than a target.

• Titrate remimazolam to clinical endpoints rather than to a propofol-derived bispectral index target
• Read the index as a trend during remimazolam sedation, not as an absolute depth
• Expect a value around 10 units higher than the equivalent propofol reading at the same clinical depth
• Do not assume a higher number means lighter sedation when remimazolam is the agent
• Expect similar emergence times between the two agents; the difference is in the monitor, not the wake-up

Why it matters

A depth monitor that reads differently by agent silently changes what a familiar number means.

Don't overread it

Sixteen healthy volunteers cannot establish agent-specific reference values, and the cognitive recovery findings were exploratory.

The statistics, in plain English

A crossover design has each volunteer act as their own control, which is why 16 people can produce a confidence interval as tight as 7.3 to 14.8 units — that interval is comfortably clear of zero, so the offset is real at these depths. Only the deep sedation comparison was confirmatory; everything else, including the cognitive findings, was exploratory and should be treated as hypothesis-generating. Healthy volunteers of physical status I are the cleanest possible population and the least like a surgical list, so the size of the offset in patients with comorbidity is unknown.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.